Importer of Controlled Substances; Notice of Application, 48780 [E9-23066]
Download as PDF
<![CDATA[
srobinson on DSKHWCL6B1PROD with NOTICES
48780
Federal Register / Vol. 74, No. 184 / Thursday, September 24, 2009 / Notices
tradition, folklore, and scientific
studies. According to scientific studies
and oral tradition the Navajo share some
cultural practices with modern
Puebloans. A preponderance of
evidence supports cultural affiliation
with modern Puebloan groups. There is
not a preponderance of evidence to
support Navajo cultural affiliation.
Officials of The Colorado College have
determined that, pursuant to 25 U.S.C.
3001 (9–10), the human remains
described above represent the physical
remains of 13 individuals of Native
American ancestry. Officials of The
Colorado College also have determined
that, pursuant to 25 U.S.C. 3001 (3)(A),
the six objects described above are
reasonably believed to have been placed
with or near individual human remains
at the time of death or later as part of
the death rite or ceremony. Lastly,
officials of The Colorado College have
determined that, pursuant to 25 U.S.C.
3001 (2), there is a relationship of
shared group identity that can be
reasonably traced between the Native
American human remains and the Hopi
Tribe of Arizona; Ohkay Owingeh, New
Mexico; Pueblo of Acoma, New Mexico;
Pueblo of Cochiti, New Mexico; Pueblo
of Isleta, New Mexico; Pueblo of Jemez,
New Mexico; Pueblo of Laguna, New
Mexico; Pueblo of Nambe, New Mexico;
Pueblo of Picuris, New Mexico; Pueblo
of Pojoaque, New Mexico; Pueblo of San
Felipe, New Mexico; Pueblo of San
Ildefonso, New Mexico; Pueblo of
Sandia, New Mexico; Pueblo of Santa
Ana, New Mexico; Pueblo of Santa
Clara, New Mexico; Pueblo of Santo
Domingo, New Mexico; Pueblo of Taos,
New Mexico; Pueblo of Tesuque, New
Mexico; Pueblo of Zia, New Mexico;
Ysleta del Sur Pueblo of Texas; and
Zuni Tribe of the Zuni Reservation, New
Mexico.
Representatives of any other Indian
tribe that believes itself to be culturally
affiliated with the human remains and
associated funerary objects should
contact Chris Melcher, Legal Counsel/
Director of Business, The Colorado
College c/o Jan Bernstein, President,
Bernstein & Associates—NAGPRA
Consultants, 1041 Lafayette St., Denver,
CO 80218, telephone (303) 894–0648,
janbernstein@nagpra.info, before
October 26, 2009. Repatriation of the
human remains and associated funerary
objects to the Hopi Tribe of Arizona may
proceed after that date if no additional
claimants come forward.
The Colorado College is responsible
for notifying the Hopi Tribe of Arizona;
Navajo Nation, Arizona, New Mexico &
Utah; Ohkay Owingeh, New Mexico;
Pueblo of Acoma, New Mexico; Pueblo
of Cochiti, New Mexico; Pueblo of
VerDate Nov<24>2008
16:27 Sep 23, 2009
Jkt 217001
Isleta, New Mexico; Pueblo of Jemez,
New Mexico; Pueblo of Laguna, New
Mexico; Pueblo of Nambe, New Mexico;
Pueblo of Picuris, New Mexico; Pueblo
of Pojoaque, New Mexico; Pueblo of San
Felipe, New Mexico; Pueblo of San
Ildefonso, New Mexico; Pueblo of
Sandia, New Mexico; Pueblo of Santa
Ana, New Mexico; Pueblo of Santa
Clara, New Mexico; Pueblo of Santo
Domingo, New Mexico; Pueblo of Taos,
New Mexico; Pueblo of Tesuque, New
Mexico; Pueblo of Zia, New Mexico;
Ysleta del Sur Pueblo of Texas; and
Zuni Tribe of the Zuni Reservation, New
Mexico that this notice has been
published.
Dated: August 17, 2009.
Sherry Hutt,
Manager, National NAGPRA Program.
[FR Doc. E9–23102 Filed 9–23–09; 8:45 am]
BILLING CODE 4312–50–S
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on July 1,
2009, Fisher Clinical Services, Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Noroxymorphone (9668),
a basic class of controlled substance
listed in schedule II.
The company plans to import the
listed substance for analytical research
and clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 26, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: September 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–23066 Filed 9–23–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Submission for OMB Review:
Comment Request
September 18, 2009.
The Department of Labor (DOL)
hereby announces the submission of the
following public information collection
requests (ICR) to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995
(Pub. L. 104–13, 44 U.S.C. chapter 35).
A copy of each ICR, with applicable
supporting documentation; including
among other things a description of the
likely respondents, proposed frequency
of response, and estimated total burden
may be obtained from the RegInfo.gov
Web site at https://www.reginfo.gov/
public/do/PRAMain or by contacting
Darrin King on 202–693–4129 (this is
not a toll-free number)/e-mail:
DOL_PRA_PUBLIC@dol.gov.
Interested parties are encouraged to
send comments to the Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for the
Department of Labor—Employee
Benefits Security Administration
(EBSA), Office of Management and
Budget, Room 10235, Washington, DC
20503, Telephone: 202–395–7316/Fax:
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 74, Number 184 (Thursday, September 24, 2009)]
[Notices]
[Page 48780]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23066]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on July 1, 2009, Fisher Clinical
Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as an importer of Noroxymorphone (9668), a basic class of
controlled substance listed in schedule II.
The company plans to import the listed substance for analytical
research and clinical trials.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than October 26, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745), all applicants
for registration to import a basic class of any controlled substance in
schedule I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: September 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-23066 Filed 9-23-09; 8:45 am]
BILLING CODE 4410-09-P
